New insights into the RNA-based mechanism of action of the anticancer drug 5′-fluorouracil in eukaryotic cells

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Mojardín, Laura ^a   Botet, Javier ^b   Quintales, Luis ^b   Moreno, Sergio ^b   Salas, Margarita ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Instituto de Biología Funcional y Genómica and Departamento de Microbiología y Genética   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; TRANSFER RNA;

ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; EUKARYOTIC CELL; EXON; FUNGAL CELL; GENE EXPRESSION; INTRON; NONHUMAN; RNA PROCESSING; RNA SPLICING; SCHIZOSACCHAROMYCES POMBE; UPREGULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; FLUOROURACIL; HUMANS; MOLECULAR SEQUENCE ANNOTATION; RNA PRECURSORS; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA SPLICING; RNA, MESSENGER; RNA, RIBOSOMAL; RNA, TRANSFER; SCHIZOSACCHAROMYCES; TRANSCRIPTION, GENETIC; URACIL;

EID: 84891409103     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078172     Document Type: Article

References (62)

1. Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338.
2. Santi DV, McHenry CS, Sommer H (1974) Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 13: 471-481.
3. Kufe DW, Major PP (1981) 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J Biol Chem 256: 9802-9805.
4. Parker WB, Cheng YC (1990) Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 48: 381-395.
5. Glazer RI, Lloyd LS (1982) Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture. Mol Pharmacol 21: 468-473.
6. Engelbrecht C, Ljungquist I, Lewan L, Yngner T (1984) Modulation of 5-fluorouracil metabolism by thymidine. In vivo and in vitro studies on RNAdirected effects in rat liver and hepatoma. Biochem Pharmacol 33: 745-750.
7. Ghoshal K, Jacob ST (1994) Specific inhibition of pre-ribosomal RNA processing in extracts from the lymphosarcoma cells treated with 5-fluorouracil. Cancer Res 54: 632-636.
8. Santi DV, Hardy LW (1987) Catalytic mechanism and inhibition of tRNA (uracil-5-)methyltransferase: evidence for covalent catalysis. Biochemistry 26: 8599-8606.
9. Zhao X, Yu YT (2007) Incorporation of 5-fluorouracil into U2 snRNA blocks pseudouridylation and pre-mRNA splicing in vivo. Nucleic Acids Res 35: 550-558.
10. Sturgeon CM, Kemmer D, Anderson HJ, Roberge M (2006) Yeast as a tool to uncover the cellular targets of drugs. Biotechnol J 1: 289-298.
11. Smith AM, Ammar R, Nislow C, Giaever G (2010) A survey of yeast genomic assays for drug and target discovery. Pharmacol Ther 127: 156-164.
12. Moreno S, Klar A, Nurse P (1991) Molecular genetic analysis of fission yeast Schizosaccharomyces pombe. Methods Enzymol 194: 795-823.
13. Quintales L, Sanchez M, Antequera F (2010) Analysis of DNA strand-specific differential expression with high density tiling microarrays. BMC Bioinformatics 11: 136.
14. Wood V, Harris MA, McDowall MD, Rutherford K, Vaughan BW, et al. (2012) PomBase: a comprehensive online resource for fission yeast. Nucleic Acids Res 40: D695-699.
15. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
16. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
17. Grivicich I, Regner A, Zanoni C, Correa LP, Jotz GP, et al. (2007) Hsp70 response to 5-fluorouracil treatment in human colon cancer cell lines. Int J Colorectal Dis 22: 1201-1208.
18. Sharma A, Upadhyay AK, Bhat MK (2009) Inhibition of Hsp27 and Hsp40 potentiates 5-fluorouracil and carboplatin mediated cell killing in hepatoma cells. Cancer Biol Ther 8: 2106-2113.
19. Li MH, Ito D, Sanada M, Odani T, Hatori M, et al. (2004) Effect of 5-fluorouracil on G1 phase cell cycle regulation in oral cancer cell lines. Oral Oncol 40: 63-70.
20. Wood V, Gwilliam R, Rajandream MA, Lyne M, Lyne R, et al. (2002) The genome sequence of Schizosaccharomyces pombe. Nature 415: 871-880.
21. Doong SL, Dolnick BJ (1988) 5-Fluorouracil substitution alters pre-mRNA splicing in vitro. J Biol Chem 263: 4467-4473.
22. Wu XP, Dolnick BJ (1993) 5-Fluorouracil alters dihydrofolate reductase premRNA splicing as determined by quantitative polymerase chain reaction. Mol Pharmacol 44: 22-29.
23. Sierakowska H, Shukla RR, Dominski Z, Kole R (1989) Inhibition of premRNA splicing by 5-fluoro-, 5-chloro-, and 5-bromouridine. J Biol Chem 264: 19185-19191.
24. Lenz HJ, Manno DJ, Danenberg KD, Danenberg PV (1994) Incorporation of 5-fluorouracil into U2 and U6 snRNA inhibits mRNA precursor splicing. J Biol Chem 269: 31962-31968.
25. Chan PP, Lowe TM (2009) GtRNAdb: a database of transfer RNA genes detected in genomic sequence. Nucleic Acids Res 37: D93-97.
26. Samuelsson T (1991) Interactions of transfer RNA pseudouridine synthases with RNAs substituted with fluorouracil. Nucleic Acids Res 19: 6139-6144.
27. Johansson MJ, Bystrom AS (2002) Dual function of the tRNA(m(5)U54) methyltransferase in tRNA maturation. RNA 8: 324-335.
28. Hellmuth K, Grosjean H, Motorin Y, Deinert K, Hurt E, et al. (2000) Cloning and characterization of the Schizosaccharomyces pombe tRNA:pseudouridine synthase Pus1p. Nucleic Acids Res 28: 4604-4610.
29. Gustavsson M, Ronne H (2008) Evidence that tRNA modifying enzymes are important in vivo targets for 5-fluorouracil in yeast. RNA 14: 666-674.
30. Wyatt MD, Wilson DM, 3rd (2009) Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci 66: 788-799.
31. Herrick D, Kufe DW (1984) Lethality associated with incorporation of 5-fluorouracil into preribosomal RNA. Mol Pharmacol 26: 135-140.
32. Lum PY, Armour CD, Stepaniants SB, Cavet G, Wolf MK, et al. (2004) Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 116: 121-137.
33. Good L, Intine RV, Nazar RN (1997) The ribosomal-RNA-processing pathway in Schizosaccharomyces pombe. Eur J Biochem 247: 314-321.
34. Butler JS (2002) The yin and yang of the exosome. Trends Cell Biol 12: 90-96.
35. Chen D, Toone WM, Mata J, Lyne R, Burns G, et al. (2003) Global transcriptional responses of fission yeast to environmental stress. Mol Biol Cell 14: 214-229.
36. Makarova OV, Makarov EM, Luhrmann R (2001) The 65 and 110 kDa SRrelated proteins of the U4/U6.U5 tri-snRNP are essential for the assembly of mature spliceosomes. EMBO J 20: 2553-2563.
37. Allen WL, Stevenson L, Coyle VM, Jithesh PV, Proutski I, et al. (2012) A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer. Mol Cancer Ther 11: 119-131.
38. Mishra SK, Ammon T, Popowicz GM, Krajewski M, Nagel RJ, et al. (2011) Role of the ubiquitin-like protein Hub1 in splice-site usage and alternative splicing. Nature 474: 173-178.
39. Webb CJ, Wise JA (2004) The splicing factor U2AF small subunit is functionally conserved between fission yeast and humans. Mol Cell Biol 24: 4229-4240.
40. Oltra E, Verde F, Werner R, D'Urso G (2004) A novel RING-finger-like protein Ini1 is essential for cell cycle progression in fission yeast. J Cell Sci 117: 967-974.
41. Das BK, Xia L, Palandjian L, Gozani O, Chyung Y, et al. (1999) Characterization of a protein complex containing spliceosomal proteins SAPs 49, 130, 145, and 155. Mol Cell Biol 19: 6796-6802.
42. Ruby SW, Chang TH, Abelson J (1993) Four yeast spliceosomal proteins (PRP5, PRP9, PRP11, and PRP21) interact to promote U2 snRNP binding to premRNA. Genes Dev 7: 1909-1925.
43. Ren L, McLean JR, Hazbun TR, Fields S, Vander Kooi C, et al. (2011) Systematic two-hybrid and comparative proteomic analyses reveal novel yeast pre-mRNA splicing factors connected to Prp19. PLoS One 6: e16719.
44. Huang B, Johansson MJ, Bystrom AS (2005) An early step in wobble uridine tRNA modification requires the Elongator complex. RNA 11: 424-436.
45. Huang B, Lu J, Bystrom AS (2008) A genome-wide screen identifies genes required for formation of the wobble nucleoside 5-methoxycarbonylmethyl-2- thiouridine in Saccharomyces cerevisiae. RNA 14: 2183-2194.
46. Umeda N, Suzuki T, Yukawa M, Ohya Y, Shindo H, et al. (2005) Mitochondria-specific RNA-modifying enzymes responsible for the biosynthesis of the wobble base in mitochondrial tRNAs. Implications for the molecular pathogenesis of human mitochondrial diseases. J Biol Chem 280: 1613-1624.
47. Suzuki T, Miyauchi K (2010) Discovery and characterization of tRNAIle lysidine synthetase (TilS). FEBS Lett 584: 272-277.
48. Zillmann M, Gorovsky MA, Phizicky EM (1991) Conserved mechanism of tRNA splicing in eukaryotes. Mol Cell Biol 11: 5410-5416.
49. Moy TI, Boettner D, Rhodes JC, Silver PA, Askew DS (2002) Identification of a role for Saccharomyces cerevisiae Cgr1p in pre-rRNA processing and 60S ribosome subunit synthesis. Microbiology 148: 1081-1090.
50. Hoang T, Peng WT, Vanrobays E, Krogan N, Hiley S, et al. (2005) Esf2p, a U3-associated factor required for small-subunit processome assembly and compaction. Mol Cell Biol 25: 5523-5534.
51. Pintard L, Bujnicki JM, Lapeyre B, Bonnerot C (2002) MRM2 encodes a novel yeast mitochondrial 21S rRNA methyltransferase. EMBO J 21: 1139-1147.
52. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, et al. (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322-1327.
53. De Angelis PM, Svendsrud DH, Kravik KL, Stokke T (2006) Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer 5: 20.
54. Griffith M, Griffith OL, Mwenifumbo J, Goya R, Morrissy AS, et al. (2010) Alternative expression analysis by RNA sequencing. Nat Methods 7: 843-847.
55. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, et al. (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236-244.
56. Zembutsu H, Ohnishi Y, Tsunoda T, Furukawa Y, Katagiri T, et al. (2002) Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res 62: 518-527.
57. Han S, Lee M, Chang H, Nam M, Park HO, et al. (2013) Construction of the first compendium of chemical-genetic profiles in the fission yeast Schizosaccharomyces pombe and comparative compendium approach. Biochem Biophys Res Commun. doi: 10.1016/j.bbrc.2013.05.138.
58. Bonnal S, Vigevani L, Valcárcel J (2012) The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov 11: 847-859.
59. Shkreta L, Froehlich U, Paquet ER, Toutant J, Elela SA, et al. (2008) Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes. Mol Cancer Ther 7: 1398-1409.
60. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, et al. (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412.
61. Edler D, Blomgren H, Allegra CJ, Johnston PG, Lagerstedt U, et al. (1997) Immunohistochemical determination of thymidylate synthase in colorectal cancer-methodological studies. Eur J Cancer 33: 2278-2281.
62. Kadota K, Huang CL, Liu D, Yokomise H, Haba R, et al. (2011) Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors. Int J Oncol 38: 355-363.